The combination of chemical and antibody inhibitors for superior P450 3A inhibition in reaction phenotyping studies

Drug Metabolism and Disposition

Volumn 36, Issue 12, 2008, Pages 2410-2413

  Rock, Dan A ^a   Foti, Robert S ^a   Pearson, Josh T ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' HYDROXYDICLOFENAC; 4' HYDROXYMEPHENYTOIN; 6ALPHA HYDROXYPACLITAXEL; 6BETA HYDROXYTESTOSTERONE; ALPHA HYDROXYMIDAZOLAM; AMFEBUTAMONE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; DEXTROMETHORPHAN; DEXTRORPHAN; DICLOFENAC; KETOCONAZOLE; MIDAZOLAM; MONOCLONAL ANTIBODY; PACLITAXEL; PARACETAMOL; PHENACETIN; RADAFAXINE; TESTOSTERONE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG METABOLISM; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MICHAELIS CONSTANT; PHENOTYPE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; HYDROXYTESTOSTERONES; KETOCONAZOLE; MICROSOMES, LIVER; MIDAZOLAM; PROTEIN ISOFORMS; TESTOSTERONE;

EID: 57349098227     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.023572     Document Type: Article

References (19)

1. Bachmann KA and Lewis JD (2005) Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 39:1064-1072.
2. Bumpus NN, Kent UM, and Hollenberg PF (2006) Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J Pharmacol Exp Ther 318:345-351.
3. Cai X, Wang RW, Edom RW, Evans DC, Shou M, Rodrigues AD, Liu W, Dean DC, and Baillie TA (2004) Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes. Drug Metab Dispos 32:584-586.
4. Gelboin HV, Krausz KW, Goldfarb I, Buters JT, Yang SK, Gonzalez FJ, Korzekwa KR, and Shou M (1995) Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem Pharmacol 50:1841-1850.
5. Ito K, Hallifax D, Obach RS, and Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837-844.
6. Lu AY, Wang RW, and Lin JH (2003) Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 31:345-350.
7. Margolis JM and Obach RS (2003) Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 31:606-611.
8. McGinnity DF, Waters NJ, Tucker J, and Riley RJ (2008) Integrated in vitro analysis for the in vivo prediction of cytochrome P450 mediated drug-drug interactions. Drug Metab Dispos 36:1126-1134.
9. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
10. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, and Tremaine LM (2005) In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78:582-592.
11. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, and Johnson EF (2008) Determinants of cytochrome P450 2c8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, or 9-cis-retinoic acid. J Biol Chem 283:17227-17237.
12. Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JC, et al. (2004) Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 32:105-112.
13. Venkatakrishnan K, Schmider J, Harmatz JS, Ehrenberg BL, von Moltke LL, Graf JA, Mertzanis P, Corbett KE, Rodriguez MC, Shader RI, et al. (2001) Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol 41:1043-1054.
14. Walsky RL, Astuccio AV, and Obach RS (2006) Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol 46:1426-1438.
15. Walsky RL, Gaman EA, and Obach RS (2005a) Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68-78.
16. Walsky RL, Obach RS, Gaman EA, Gleeson JP, and Proctor WR (2005b) Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 33:413-418.
17. Wang RW, Newton DJ, Liu NY, Shou M, Rushmore T, and Lu AY (1999) Inhibitory anti-CYP3A4 peptide antibody: mapping of inhibitory epitope and specificity toward other CYP3A isoforms. Drug Metab Dispos 27:167-172.
18. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833.
19. Zhang H, Davis CD, Sinz MW, and Rodrigues AD (2007) Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667-687.